These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30877679)

  • 21. Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.
    Domnich A; Gasparini R; Amicizia D; Boccadifuoco G; Giuliani MM; Panatto D
    J Immunol Res; 2015; 2015():353461. PubMed ID: 26351645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries.
    Abad R; Medina V; Stella M; Boccadifuoco G; Comanducci M; Bambini S; Muzzi A; Vázquez JA
    PLoS One; 2016; 11(3):e0150721. PubMed ID: 26950303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
    Borrow R; Taha MK; Giuliani MM; Pizza M; Banzhoff A; Bekkat-Berkani R
    J Infect; 2020 Dec; 81(6):862-872. PubMed ID: 32745637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.
    Donnelly J; Medini D; Boccadifuoco G; Biolchi A; Ward J; Frasch C; Moxon ER; Stella M; Comanducci M; Bambini S; Muzzi A; Andrews W; Chen J; Santos G; Santini L; Boucher P; Serruto D; Pizza M; Rappuoli R; Giuliani MM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19490-5. PubMed ID: 20962280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4CMenB journey to the 10-year anniversary and beyond.
    Abitbol V; Martinón-Torres F; Taha MK; Nolan T; Muzzi A; Bambini S; Borrow R; Toneatto D; Serino L; Rappuoli R; Pizza M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357924. PubMed ID: 38976659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment.
    Parikh SR; Newbold L; Slater S; Stella M; Moschioni M; Lucidarme J; De Paola R; Giuliani M; Serino L; Gray SJ; Clark SA; Findlow J; Pizza M; Ramsay ME; Ladhani SN; Borrow R
    Lancet Infect Dis; 2017 Jul; 17(7):754-762. PubMed ID: 28366725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
    Pajon R; Lujan E; Granoff DM
    Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.
    Chiu NC; Huang LM; Willemsen A; Bhusal C; Arora AK; Reynoso Mojares Z; Toneatto D
    Hum Vaccin Immunother; 2018 May; 14(5):1075-1083. PubMed ID: 29337653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.
    Lee HJ; Choe YJ; Hong YJ; Kim KH; Park SE; Kim YK; Oh CE; Lee H; Song H; Bock H; Casula D; Bhusal C; Arora AK
    Vaccine; 2016 Feb; 34(9):1180-6. PubMed ID: 26826544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase Variation of NadA in Invasive Neisseria meningitidis Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine.
    Green LR; Lucidarme J; Dave N; Chan H; Clark S; Borrow R; Bayliss CD
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29950334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic and genotypic characterization of meningococcal isolates in Tunis, Tunisia: High diversity and impact on vaccination strategies.
    Brik A; Terrade A; Hong E; Deghmane A; Taha MK; Bouafsoun A; Khmiri M; Boussetta K; Boukhir S; Jaballah NB; Kechrid A; Smaoui H
    Int J Infect Dis; 2020 Feb; 91():73-78. PubMed ID: 31756567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal.
    Simões MJ; Bettencourt C; De Paola R; Giuliani M; Pizza M; Moschioni M; Machado J
    PLoS One; 2017; 12(5):e0176177. PubMed ID: 28459837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic variability of Polish serogroup B meningococci (2010-2016) including the 4CMenB vaccine component genes.
    Waśko I; Gołębiewska A; Kiedrowska M; Ronkiewicz P; Wróbel-Pawelczyk I; Kuch A; Hong E; Skoczyńska A
    Vaccine; 2020 Feb; 38(8):1943-1952. PubMed ID: 31980191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sequencing analysis of the antigens included in the four-component  vaccine against serogroup B meningococcus in Czech isolates of Neisseria meningitidis from 2007-2013].
    Křížová P; Musílek M; Vacková Z; Bečvářová Z; Kozáková J
    Epidemiol Mikrobiol Imunol; 2014 Feb; 63(1):61-8. PubMed ID: 24730996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017).
    Tzanakaki G; Xirogianni A; Tsitsika A; Clark SA; Kesanopoulos K; Bratcher HB; Papandreou A; Rodrigues CMC; Maiden MCJ; Borrow R; Tsolia M
    Vaccine; 2021 Mar; 39(11):1621-1630. PubMed ID: 33597116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial.
    Martinón-Torres F; Safadi MAP; Martinez AC; Marquez PI; Torres JCT; Weckx LY; Moreira ED; Mensi I; Calabresi M; Toneatto D
    Vaccine; 2017 Jun; 35(28):3548-3557. PubMed ID: 28533054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.
    Lucidarme J; Gilchrist S; Newbold LS; Gray SJ; Kaczmarski EB; Richardson L; Bennett JS; Maiden MC; Findlow J; Borrow R
    Clin Vaccine Immunol; 2013 Sep; 20(9):1360-9. PubMed ID: 23803905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.